ATOSSA THERAPEUTICS I
0.8462
12-May-25 12:21:35
15 minutes delayed
Stocks
+0.0295
+3.61%
Today's range
0.8302 - 0.8603
ISIN
N/A
Source
NASDAQ
-
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
20 Nov 2023 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 2023 09:00:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
09 Nov 2023 09:00:00 By Nasdaq GlobeNewswire
-
Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
18 Sep 2023 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 2023 08:30:03 By Nasdaq GlobeNewswire
-
08 Aug 2023 09:00:00 By Nasdaq GlobeNewswire
-
20 Jul 2023 09:15:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
13 Jul 2023 16:15:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
10 Jul 2023 09:15:00 By Nasdaq GlobeNewswire
-
06 Jul 2023 09:15:00 By Nasdaq GlobeNewswire
-
28 Jun 2023 09:15:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces $10M Stock Repurchase Program
27 Jun 2023 09:15:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
22 Jun 2023 16:15:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
21 Jun 2023 10:13:54 By Nasdaq GlobeNewswire
-
Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC
14 Jun 2023 09:15:00 By Nasdaq GlobeNewswire
-
12 Jun 2023 09:15:00 By Nasdaq GlobeNewswire
-
01 Jun 2023 09:10:00 By Nasdaq GlobeNewswire